Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] AndroGel Antitrust Litigation Andro Gel Antitrust Litigation [Member] Represents information pertaining to AndroGel Antitrust Litigation. Niaspan Niaspan [Member] Represents information pertaining to Niaspan, a product of the entity. Elliott Associates, L.P. Elliott Associates, L.P. [Member] Represents information pertaining to Elliot Associates, LP. Testosterone Replacement Therapy Products Liability Litigation Testosterone Replacement Therapy Products Liability Litigation [Member] Information relating to Testosterone Replacement Therapy Products Liability Litigation. Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member] Novartis Vaccines and Diagnostics Inc and Grifols Worldwide Operations Ltd [Member] Novartis Vaccines and Diagnostics, Inc. and Grifols Worldwide Operations Ltd. Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency Nature [Domain] Loss Contingency, Nature [Domain] Disgorgement remedy DisgorgementRemedy [Member] Disgorgement remedy Depakote Depakote [Member] Represents information concerning Depakote-related claims. Legal Proceedings and Contingencies Loss Contingencies [Line Items] Recorded accrual balance for litigation Loss Contingency Accrual Number of generic companies with whom certain litigation related agreements were entered into Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws. Number of individual plaintiff lawsuits Loss Contingency Individual Plaintiff Lawsuits Number Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period. Number of purported class actions Loss Contingency Purported Class Actions Number Represents the number of purported class actions filed, pertaining to a loss contingency during the period. Number of healthcare benefit providers who filed lawsuits Loss Contingency, Number of Plaintiffs Damages awarded against company Loss Contingency, Damages Awarded, Value Number of individual putative class action lawsuit Putative Class Action Lawsuit Individual Number Represents number of the number of individual putative class action lawsuit. Number of parties to lawsuit (in investment funds) Loss Contingency, New Claims Filed, Number Numbers of claims consolidated for pre-trial purposes Number Of Claims Consolidated For Pre-Trial Purposes Numbers of claims are consolidated for pre-trial purposes. Number of claims pending Loss Contingency, Pending Claims, Number Percentage of claims subject to settlement agreements Percentage of Claims Subject to Settlement Agreements Percentage of claims subject to settlement agreements HCV-related patents Gain Contingency, Patents Allegedly Infringed upon, Number Leases [Abstract] Summary of amounts and location of operating and finance leases on the condensed consolidated balance sheet Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Operating and Finance Lease Balance Sheet Disclosure [Table Text Block] Summary of lease costs recognized in the condensed consolidated statement of earnings Lease, Cost [Table Text Block] Schedule of weighted-average remaining lease term and weighted-average discount rate for operating and finance leases Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] Operating and Finance Lease Weighted-Average Remaining Lease Term and Discount Rate [Table Text Block] Schedule of supplementary cash flow information regarding the company's operating and finance leases Operating and Finance Lease Cash Flow Disclosure [Table Text Block] Operating and Finance Lease Cash Flow Disclosure [Table Text Block] Summary of future maturities of AbbVie's operating lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Summary of future maturities of AbbVie's finance lease liabilities Finance Lease, Liability, Maturity [Table Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Stockholders' Equity Note [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification out of Accumulated Other Comprehensive Income [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Pension and post- employment benefits Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Cash flow hedging activities Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Significant amounts reclassified out of each component of AOCI Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] Reclassifications from accumulated other comprehensive income, before tax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Tax (benefit) expense Reclassification from AOCI, Current Period, Tax Reclassifications from accumulated other comprehensive income, after tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Organization, Consolidation and Presentation of Financial Statements [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle New Accounting Pronouncements or Change in Accounting Principle [Line Items] Other assets Other Assets, Noncurrent Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Other long-term liabilities Liabilities, Other than Long-term Debt, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock Options Employee Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Weighted-average grant-date fair value of the stock options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Period for recognition of unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Goodwill and Intangible Assets Disclosure [Abstract] Changes in the carrying amount of goodwill Goodwill [Roll Forward] Balance at the beginning of the period Goodwill Foreign currency translation adjustments Goodwill, Translation and Purchase Accounting Adjustments Balance at the end of the period Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss [Abstract] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Collaboration with Janssen Biotech, Inc. No definition available. Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Janssen Biotech Inc Janssen Biotech Inc [Member] Represents the information pertains to the entity Janssen Biotech Inc. Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative arrangement Collaborative Arrangement [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Collaborative and license agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Milestone payments Collaborative Arrangement Milestone Method Payments Receivable The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement. Share of collaboration development costs responsible by Janssen (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement. Share of collaboration development costs responsible by the entity (as a percent) Collaborative Arrangements Percentage Of Share Of Development Costs Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement. United States - Janssen's share of profits (included in cost of products sold) Collaborative Arrangements Payment To Other Party As Share Of Profits Before Income Taxes Represents the amount paid or to be paid to other party as profit sharing in the contract which is recorded as expense for the company. International - AbbVie's share of profits (included in net revenues) Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Global - AbbVie's share of other costs (included in respective line items) Cost Sharing Expenses Represents cost sharing expenses. Accounts receivable, net Accounts Receivable, Net, Current Postemployment Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Defined benefit plans Pension Plan [Member] Other post-employment plans Other Postretirement Benefits Plan [Member] Defined benefit and other post-employment plans Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of actuarial losses and prior service cost (credit) Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit) The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost. Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] December 2018 Stock Repurchase Authorization December 2018 Stock Repurchase Authorization [Member] December 2018 Stock Repurchase Authorization February 2017 Stock Repurchase Program February 2017 Stock Repurchase Program [Member] February 2017 Stock Repurchase Program Equity, Class of Treasury Stock Equity, Class of Treasury Stock [Line Items] Shares repurchased (in shares) Treasury Stock, Shares, Acquired Payment for shares repurchased Treasury Stock, Value, Acquired, Cost Method Remaining share repurchase authorization amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Summary of share-based compensation expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of quarterly cash dividends Schedule of Dividends Payable [Table Text Block] Summary of changes in balances of each component of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Statement of Comprehensive Income [Abstract] Net earnings Net Income (Loss) Attributable to Parent Foreign currency translation adjustments, net of tax expense (benefit) of $1 for the three months ended March 31, 2019 and $(3) for the three months ended March 31, 2018 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Net investment hedging activities, net of tax expense (benefit) of $19 for the three months ended March 31, 2019 and $(30) for the three months ended March 31, 2018 Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax, Portion Attributable to Parent Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity. Pension and post-employment benefits, net of tax expense (benefit) of $6 for the three months ended March 31, 2019 and $9 for the three months ended March 31, 2018 Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Marketable security activities, net of tax expense (benefit) of $— for the three months ended March 31, 2019 and $— for the three months ended March 31, 2018 Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Cash flow hedging activities, net of tax expense (benefit) of $(7) for the three months ended March 31, 2019 and $(1) for the three months ended March 31, 2018 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Book value Reported Value Measurement [Member] Approximate fair value Estimate of Fair Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Bases used to measure the approximate fair values of the financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities Liabilities, Fair Value Disclosure [Abstract] Short-term borrowings Short-term Debt, Fair Value Current portion of long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future. Long-term debt and finance lease obligations, excluding fair value hedges Long Term Debt and Capital Lease Obligations Fair Value Disclosure Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date. Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Carrying amount of investments in equity securities that do not have readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Collaboration with Janssen Biotech, Inc. Collaborative Arrangement Disclosure [Text Block] Segment Reporting [Abstract] Number of operating segments Number of Operating Segments Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Commercial paper Commercial Paper [Member] Term loan facilities Loans Payable [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] May 2018 term loan credit agreement May 2018 Term Loan Credit Agreement [Member] May 2018 Term Loan Credit Agreement Short-Term Borrowings Short-term Debt [Line Items] Short-term borrowings Short-term Debt Weighted-average interest rate on commercial paper (as a percent) Short-term Debt, Weighted Average Interest Rate, at Point in Time Repayments of other short-term borrowings Repayments of Other Short-term Debt Term loan credit agreement term Debt Instrument, Term Statement of Financial Position [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Common stock held in treasury, at cost (in shares) Treasury Stock, Shares Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of products sold Cost of Sales [Member] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Pre-tax compensation expense Allocated Share-based Compensation Expense Tax benefit Employee Service Share-based Compensation, Tax Benefit from Compensation Expense After-tax compensation expense Allocated Share-based Compensation Expense, Net of Tax Equity Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Foreign currency translation adjustments, tax expense (benefit) Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent Net investment hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Net Investment Hedge, Tax, Portion Attributable to Parent Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge, attributable to parent entity. Pension and post-employment benefits, tax expense (benefit) Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Marketable security activities, tax expense (benefit) Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Cash flow hedging activities, tax expense (benefit) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Operating cash flows from operating leases Operating Lease, Payments Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Financing cash flows from finance leases Finance Lease, Principal Payments Right-of-use assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Amortization of intangible assets Amortization of Intangible Assets Definite-lived intangible assets impairment charges Impairment of Intangible Assets, Finite-lived Earnings Per Share [Abstract] Basic EPS Earnings Per Share, Basic, Two Class Method [Abstract] Net earnings Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Basic Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Basic earnings per share (in dollars per share) Earnings Per Share, Basic Diluted EPS Earnings Per Share, Diluted, Two Class Method [Abstract] Earnings allocated to participating securities Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Earnings available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Weighted-average basic shares outstanding (in shares) Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Accounts receivable, net Accounts Receivable [Member] Total revenues Sales Revenue, Net [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Risk Geographic Concentration Risk [Member] HUMIRA Product Concentration Risk [Member] Concentration of Risk Concentration Risk [Line Items] Number of principal customers Number of Principal US Customers Represents the number of principal U.S. customers of the entity. Concentrations risk (as a percent) Concentration Risk, Percentage Financial Instruments and Fair Value Measures Derivatives and Fair Value [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustments to reconcile net earnings to net cash from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Change in fair value of contingent consideration liabilities Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Stock-based compensation Share-based Compensation Upfront costs and milestones related to collaborations Upfront Costs Related To Collaborations Represents the amount of upfront costs related to collaborations reported in the statement of cash flows. Other, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Acquisitions and investments Payments to Acquire Other Investments Acquisitions of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of investment securities Payments to Acquire Marketable Securities Sales and maturities of investment securities Proceeds from Sale, Maturity and Collection of Investments Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net change in commercial paper borrowings Proceeds from (Repayments of) Commercial Paper Repayments of other short-term borrowings Repayments of long-term debt and lease obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Dividends paid Payments of Dividends Purchases of treasury stock Payments for Repurchase of Common Stock Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Other, net Proceeds from (Payments for) Other Financing Activities Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net change in cash and equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and equivalents, end of period Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Segment Information Segment Reporting Disclosure [Text Block] Schedule of profit and cost sharing relationship Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] RSUs and Performance Shares Restricted Stock Units And Performance Shares [Member] Restricted Stock Units And Performance Shares [Member] Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Fair market value of awards vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Supplemental Financial Information Schedule of interest expense, net Interest Income and Interest Expense Disclosure [Table Text Block] Schedule of inventories Schedule of Inventory, Current [Table Text Block] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Operating leases Operating Lease Liabilities, Payments Due [Abstract] 2019 Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four 2023 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability Finance leases Finance Lease Liabilities, Payments, Due [Abstract] 2019 Finance Lease, Liability, Payments, Remainder of Fiscal Year 2020 Finance Lease, Liability, Payments, Due Year Two 2021 Finance Lease, Liability, Payments, Due Year Three 2022 Finance Lease, Liability, Payments, Due Year Four 2023 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total lease payments Finance Lease, Liability, Payments, Due Less: Interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability Total Lease Liabiltiies, Payments, Due [Abstract] Lease Liabilities, Payments, Due 2019 Lease, Liability, Payments, Remainder of Fiscal Year Amount of lessee's undiscounted obligation for lease payments for operating and finance leases having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year. 2020 Lease, Liability, Payments, Due Year Two Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in second fiscal year following latest fiscal year. 2021 Lease, Liability, Payments, Due Year Three Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in third fiscal year following latest fiscal year. 2022 Lease, Liability, Payments, Due Year Four Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fourth fiscal year following latest fiscal year. 2023 Lease, Liability, Payments, Due Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due in fifth fiscal year following latest fiscal year. Thereafter Lease, Liability, Payments, Due after Year Five Amount of lessee's undiscounted obligation for lease payments for operating and finance leases, due after fifth fiscal year following latest fiscal year. Total lease payments Lease, Liability, Payments, Due Amount of lessee's undiscounted obligation for lease payments for operating and finance leases. Less: Interest Lease, Liability, Undiscounted Excess Amount Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating and finance leases. Present value of lease liabilities Lease, Liability Present value of lessee's discounted obligation for lease payments from operating and finance leases. Contractual minimum lease payments for leases executed but not yet commenced Lessee, Lease, Lease Not yet Commenced, Contractual Minimum Payments Amount of lessee's contractual minimum lease payments for operating and finance leases that have not yet commenced. Lease term for leases executed but not yet commenced Lessee, Lease, Lease Not yet Commenced, Term of Contract Lessee, Lease, Lease Not yet Commenced, Term of Contract Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other assets Other Noncurrent Assets [Member] Property and equipment, net Property, Plant and Equipment [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Current portion of long-term debt and finance lease obligations LongTermDebtandFinanceLeaseObligationsCurrent [Member] Refers to long-term debt and finance lease obligations due within one year or the normal operating cycle, if longer. Long-term debt and finance lease obligations LongTermDebtandFinanceLeaseObligations [Member] Refers to long-term debt and finance lease obligations due after one year or beyond the normal operating cycle, if longer. Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Assets Assets [Abstract] Operating lease assets Operating Lease, Right-of-Use Asset Finance lease assets Finance Lease, Right-of-Use Asset Total lease assets Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating and finance leases. Liabilities Liabilities [Abstract] Current operating lease liabilities Operating Lease, Liability, Current Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Current finance lease liabilities Finance Lease, Liability, Current Noncurrent finance lease liabilities Finance Lease, Liability, Noncurrent Total lease liabilities Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Foreign currency forward exchange contracts Foreign Exchange Forward [Member] Interest rate swaps designated as fair value hedges Interest Rate Swap [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior notes Senior Notes [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash Flow Hedges Cash Flow Hedging [Member] Fair Value Hedges Fair Value Hedging [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Designated as hedging instrument Designated as Hedging Instrument [Member] Not designated as hedges Not Designated as Hedging Instrument [Member] Net foreign exchange loss Foreign Currency Gain (Loss) [Member] Interest expense, net Interest Expense [Member] Gain (loss) on derivatives Derivative Instruments, Gain (Loss) [Line Items] Pre-tax gains (losses) from derivative instruments recognized in other comprehensive income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Foreign currency cash flow hedge gain expected to be reclassified during next 12 months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Pre-tax gains (losses) from non-derivative net investment hedge recognized in other comprehensive income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Derivative gain (loss), net Derivative, Gain (Loss) on Derivative, Net Debt designated as hedged item in fair value hedges gain (loss) Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge Summary of net periodic benefit costs Schedule of Net Benefit Costs [Table Text Block] Interest Expense, Net Interest Revenue (Expense), Net [Abstract] Interest expense Interest Expense Interest income Investment Income, Interest Interest expense, net Interest Income (Expense), Nonoperating, Net Inventories Inventory, Net [Abstract] Finished goods Inventory, Finished Goods, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Raw materials Inventory, Raw Materials, Net of Reserves Inventories Inventory, Net Property and Equipment Property, Plant and Equipment, Net [Abstract] Property and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Depreciation expense Licensing, Acquisitions, and Other Arrangements Licensing, Acquisitions, and Other Arrangements Acquisitions Collaborations and Other Arrangements Disclosure [Text Block] The entire disclosure for acquisitions, collaborations and other arrangements of the entity. Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of worldwide net revenues Disaggregation of Revenue [Table Text Block] Schedule of diluted earnings per share, impact of two-class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net investment hedging activities Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member] Accumulated Net Gain (Loss) From Net Investment Hedges Attributable To Parent [Member] Marketable security activities Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax AOCI Attributable to Parent, Net of Tax [Roll Forward] Beginning balance Stockholders' Equity Attributable to Parent Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Net losses (gains) reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Ending balance Cash outflows related to acquisitions and investments Acquired in-process research and development Research and Development Asset Acquired Other than Through Business Combination, Written-off Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed product rights Developed Technology Rights [Member] License agreements Licensing Agreements [Member] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Gross carrying amount Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Net carrying amount Finite-Lived Intangible Assets, Net Indefinite-lived research and development Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In-Process Research and Development In Process Research and Development [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Stemcentrx Inc. Stemcentrx Inc. [Member] Represents the information pertaining to acquisition of Stemcentrx, Inc. Indefinite-lived Intangible Assets Indefinite-lived Intangible Assets [Line Items] Indefinite-lived intangible asset impairment charges Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Indefinite-lived research and development assets Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Short-term investments Short-term Investments [Member] Asset backed securities Asset-backed Securities [Member] Corporate debt securities Corporate Debt Securities [Member] Other debt securities Other Debt Obligations [Member] Available-for-sale Securities Debt Securities, Available-for-sale [Line Items] Debt securities Debt Securities, Available-for-sale Maximum maturity period of long-term debt securities (in years) Debt Securities, Available-for-sale, Term Amortized cost Available-for-sale Securities, Amortized Cost Basis Gross unrealized, Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized, Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair value Available-for-sale Securities Other-than-temporary impairments Accumulated Other Comprehensive Income (Loss), Other than Temporary Impairment, Not Credit Loss, Net of Tax, Available-for-sale, Debt Securities Leases Lessee, Leases [Policy Text Block] Short-Term Leases Short-term Leases [Policy Text Block] Effective tax rate Effective Income Tax Rate Reconciliation, Percent U.S. statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Potential change in unrecognized tax benefits Decrease in Unrecognized Tax Benefits is Reasonably Possible Cash dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Operating lease cost Operating Lease, Cost Finance lease amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Finance lease interest on lease liabilities Finance Lease, Interest Expense Short-term lease cost Short-term Lease, Cost Variable lease cost Variable Lease, Cost Total lease cost Lease, Cost Derivative [Table] Derivative [Table] Not designated as hedging instrument Interest rate contracts Net Investment Hedges Net Investment Hedging [Member] Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Other long-term liabilities Other Liabilities [Member] Derivative instruments, notional amount and fair value Derivatives, Fair Value [Line Items] Notional amount of derivative instruments Derivative, Notional Amount Duration of forward exchange contracts Derivative, Term of Contract Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold Maximum Length of Time Hedged in Cash Flow Hedge Principal amount of unsecured senior notes Debt Instrument, Face Amount Foreign currency contracts in asset position Derivative Asset, Fair Value, Gross Asset Foreign currency contracts in liability position Derivative Liability, Fair Value, Gross Liability Income Statement [Abstract] Net revenues Revenues Cost of products sold Cost of Goods and Services Sold Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total operating costs and expenses Costs and Expenses Operating earnings Operating Income (Loss) Interest expense, net Net foreign exchange loss Foreign Currency Transaction Gain (Loss), before Tax Other (income) expense, net Other Nonoperating Income (Expense) Earnings before income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net earnings Per share data Earnings Per Share, Basic and Diluted [Abstract] Weighted-average diluted shares outstanding (in shares) Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Common stock Common Stock [Member] Treasury stock Treasury Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Retained earnings Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Adoption of new accounting standards Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income, net of tax Dividends declared Dividends, Common Stock, Cash Purchases of treasury stock Purchases of treasury stock (in shares) Stock-based compensation plans and other Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock-based compensation plans and other (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Ending balance (in shares) Restructuring and Related Activities [Abstract] Restructuring charges Restructuring Charges Restructuring reserve activity Restructuring Reserve [Roll Forward] Accrued balance beginning of the period Restructuring Reserve Restructuring charges Restructuring Reserve Cash Settled Restructuring Charges The change in the restructuring reserve related to the amount of restructuring charges during the period that are expected to be cash settled. Payments and other adjustments Restructuring Reserve Period Cash Settled and Other Adjustments The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period. Accrued balance end of the period Transfers of assets or liabilities between the fair value measurement levels Fair Value, Transfers Between Level 1 and Level 2, Description and Policy [Abstract] Transfer of assets from level 1 to level 2 Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Transfer of assets from level 2 to level 1 Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Transfer of liabilities from level 1 to level 2 Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount Transfer of liabilities from level 2 to level 1 Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3) Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Change in fair value recognized in net earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Ending balance Document and Entity Information Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Earnings Per Share Earnings Per Share [Text Block] Leases Leases of Lessee Disclosure [Text Block] Weighted-average remaining lease term for operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term for finance leases Finance Lease, Weighted Average Remaining Lease Term Weighted-average discount rate for operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate for finance leases Finance Lease, Weighted Average Discount Rate, Percent Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Investment Type [Axis] Investment Type [Axis] Investment Type Categorization [Member] Investments [Domain] Time deposits Bank Time Deposits [Member] Foreign Currency Contract Foreign Exchange Contract [Member] Changes Measurement Changes Measurement [Member] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Axis] Contingent Consideration Change, By Type [Domain] Contingent Consideration Change, By Type [Domain] [Domain] for Contingent Consideration Change, By Type [Axis] Change In Assumed Discount Rate Change In Assumed Discount Rate [Member] Change In Assumed Discount Rate [Member] Change In Assumed Probability Rate Change In Assumed Probability Rate [Member] Change In Assumed Probability Rate [Member] Fair value, asset and liability measures Assets Assets, Fair Value Disclosure [Abstract] Cash and equivalents Cash and Cash Equivalents, Fair Value Disclosure Time deposits Investments, Fair Value Disclosure Equity securities Available-for-sale Securities, Equity Securities Foreign currency contracts Total assets Assets, Fair Value Disclosure Interest rate hedges Interest Rate Derivative Liabilities, at Fair Value Foreign currency contracts Contingent consideration Business Combination, Contingent Consideration, Liability Discount rate change Fair Value Inputs, Discount Rate Change Fair Value Inputs, Assumed Discount Rate Change Contingent consideration liability change Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Potential Change in Amount of Contingent Consideration, Liability Assumed probability rate change Fair Value Inputs, Assumed Probability Rate Change Fair Value Inputs, Assumed Probability Rate Change Summary of changes in the carrying amount of goodwill Schedule of Goodwill [Table Text Block] Summary of definite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of indefinite-lived intangible assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Key Product Portfolio [Axis] Key Product Portfolio [Axis] Information concerning the company's portfolios of key products. Key Product Portfolio [Domain] Key Product Portfolio [Domain] [Domain] for Information concerning the company's portfolios of key products. Immunology Immunology [Member] Represents information pertaining to Immunology, a key product portfolio of the entity. Hematologic Oncology Hematologic Oncology [Member] Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity. HCV HCV [Member] Represents information pertaining to HCV, a key product portfolio of the entity. Other Key Products Other Key Products [Member] Represents information pertaining to other key products of the entity. Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] HUMIRA H U M I R A [Member] Represents information pertaining to HUMIRA, a product of the entity. IMBRUVICA Imbruvica [Member] Represents information pertaining to Imbruvica, a product of the entity. VENCLEXTA VENCLEXTA [Member] Represents information pertaining to VENCLEXTA, a product of the entity. MAVYRET MAVYRET [Member] Represents information pertaining to MAVYRET, a product of the entity. VIEKIRA VIEKIRA [Member] Represents information pertaining to VIEKIRA, a product of the entity. Creon Creon [Member] Represents information pertaining to Creon, a product of the entity. Lupron Lupron [Member] Represents information pertaining to Lupron, a product of the entity. Synthroid Synthroid [Member] Represents information pertaining to Synthroid, a product of the entity. Synagis Synagis [Member] Represents information pertaining to Synagis, a product of the entity. Duodopa Duodopa [Member] Represents information pertaining to Duodopa, a product of the entity. Sevoflurane Sevoflurane [Member] Represents information pertaining to Sevoflurane, a product of the entity. Kaletra Kaletra [Member] Represents information pertaining to Kaletra, a product of the entity. AndroGel Andro Gel [Member] Represents information pertaining to AndroGel, a product of the entity. All other Other Products [Member] Represents information pertaining to other products of the entity not specified anywhere. Disaggregation of Revenue Disaggregation of Revenue [Line Items] Net revenues Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenues Total net revenues Current assets Assets, Current [Abstract] Cash and equivalents Short-term investments Short-term Investments Inventories Prepaid expenses and other Prepaid Expense and Other Assets Total current assets Assets, Current Investments Long-term Investments Property and equipment, net Intangible assets, net Goodwill Total assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Current portion of long-term debt and finance lease obligations Long-term Debt and Capital Lease Obligations, Current Total current liabilities Liabilities, Current Long-term debt and finance lease obligations Long-term Debt and Capital Lease Obligations Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Commitments and contingencies Commitments and Contingencies Stockholders’ equity (deficit) Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,780,885,882 shares issued as of March 31, 2019 and 1,776,510,871 as of December 31, 2018 Common Stock, Value, Outstanding Common stock held in treasury, at cost, 302,648,065 shares as of March 31, 2019 and 297,686,473 as of December 31, 2018 Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity (deficit) Total liabilities and equity Liabilities and Equity Summary of amounts and location of derivatives on the condensed consolidated balance sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of pre-tax amounts of derivatives recognized in other comprehensive income (loss) Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block] Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings Derivative Instruments, Gain (Loss) [Table Text Block] Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of changes in fair value of Level 3 inputs Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of book values, approximate fair values and bases used to measure certain financial instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Summary of available-for-sale securities by type Available-for-sale Securities [Table Text Block] Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Summary of the cash activity in the restructuring reserve Restructuring and Related Costs [Table Text Block] Legal Proceedings and Contingencies Legal Matters and Contingencies [Text Block]